Affimed Therapeutics (AFMD)

Affimed Therapeutics is a mid-clinical stage biotech company focused on exploring its proprietary NK- and T-cell engaging bi- and tri- specific antibodies, called TandAbs as a novel cancer treatment modality. NK and T-cell engaging specific antibodies are designed to bring NK-cells or T-cells into a closer proximity of  cancer cells and trigger a signal cascade leading to the destruction of the latter. The major benefits of bi- and tri- specific antibodies is to circumvent the normal regulatory constraints of the NK- and T-cells and enable these cytotoxic cells to eradicate cancer cells directly. Affimed is the leading developer of NK-cell engaging bi- and tri- specific antibodies.   The two initial indications addressed by the company’s lead products, AFM13 and AFM11 are Hodgkin and Non-Hodgkin Lymphoma. The company plans to potentially report AFM13 in Hodgkin’s Lymphoma (HL) Phase IIa results in 1H16, and AFM11 in Non-Hodgkin’s Lymphoma (NHL) and acute lymphoblastic leukemia (ALL) Phase I interim study results in2H16. Additionally, they plan to initiate an AFM13 / CPI combination Phase I study in HL in mid-2016 with data potentially available in late 2016/2017. All indications are of orphan indications and have high unmet medical needs.  Should the ALL clinical study be successful, the proprietary TandAB antibody could potentially have treatment utility in several other cancers.

Published Reports

AFMD-2018-12-10-R&D day recap
AFMD-2018-12-04-ASH recap
AFMD-2018-11-07-3Q18
AFMD-2018-10-09-AFM11 on clinical hold
AFMD-2018-08-28-Genentech deal
AFMD-2018-08-09-2Q18
AFMD-2018-05-16-1Q18
AFMD-2018-03-21-4Q17
AFMD-2017-12-12-ASH report
AFMD-2017-08-02-2Q17 rev
AFMD-2017-05-18-1Q17 rev4
AFMD-2017-04-06-AACR re-cap rev
AFMD-2017-03-31-4Q16 rev
AFMD-2017-03-03-2017-AACR abstracts (1) rev
AFMD-2016-12-12-Mgmt meetings after ASH rev2
afmd-2016-11-15-mgmt-meetings-rev
afmd-2016-11-02-3q16-rev
AFMD-2016-08-11-2Q16 rev
AFMD-2016-07-14-Management update revb
AFMD-2016-05-18-1Q16 (1) rev
AFMD-2016-03-31-4Q15 (1) rev
AFMD-2016-01-27-HL Day takeaway
AFMD-2016-01-25-AFM13-PD1 combo P1 to start
AFMD-2015-12-10-Initiation-final